Aquestive Therapeutics (AQST) PT Raised to $10 at Lake Street Capital Markets

Lake Street Capital Markets analyst Thomas Flaten raised the price target on Aquestive Therapeutics (NASDAQ: AQST) to $10.00 (from $7.00) while maintaining a Buy rating.

The analyst commented: "We are raising our price target to more appropriately reflect Anaphylm catalysts over the coming 12-15 months, the expansion of the Company’s pipeline, and multiple expansion. Our $10 price target is comprised of (i) $2 per share derived by applying a 3x EV/Revenue multiple (in line with comparable companies) to our 2025 partnered revenue estimate of $51.0M and (ii) $8 per share attributed to Anaphylm, representing a 50% to ARS Pharmaceuticals’ (SPRY; NR) current market valuation. We apply this discount to account for neffy’s more advanced stage of development."

You May Also Be Interested In

• Compass Point Upgrades Circle Internet Group (CRCL) to Buy, 'a tactical trade into YE2026 and 4Q26 results'
• Calumet restructures Montana Renewables deal with Warburg Pincus
• Galectin Therapeutics presents belapectin data at AASLD 2026